DB:1T3

Stock Analysis Report

Executive Summary

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.

Snowflake

Flawless balance sheet and slightly overvalued.

Share Price & News

How has Syndax Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1T3's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

5.8%

1T3

5.5%

DE Biotechs

-0.3%

DE Market


1 Year Return

49.9%

1T3

-1.9%

DE Biotechs

10.9%

DE Market

Return vs Industry: 1T3 exceeded the German Biotechs industry which returned -1.9% over the past year.

Return vs Market: 1T3 exceeded the German Market which returned 10.9% over the past year.


Shareholder returns

1T3IndustryMarket
7 Day5.8%5.5%-0.3%
30 Day11.3%-0.8%2.6%
90 Day-25.9%-4.8%11.8%
1 Year49.9%49.9%-1.6%-1.9%14.4%10.9%
3 Year-31.5%-31.5%65.5%63.4%24.1%13.2%
5 Yearn/a7.2%4.8%33.0%14.8%

Price Volatility Vs. Market

How volatile is Syndax Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Syndax Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1T3 (€6.4) is trading below our estimate of fair value (€132.75)

Significantly Below Fair Value: 1T3 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1T3 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 1T3 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1T3's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1T3 is overvalued based on its PB Ratio (4.3x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is Syndax Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

28.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1T3 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1T3 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1T3 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 1T3's revenue (81.2% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: 1T3's revenue (81.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1T3 is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Syndax Pharmaceuticals performed over the past 5 years?

-4.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1T3 has high quality earnings.

Growing Profit Margin: 1T3 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1T3 is unprofitable, and losses have increased over the past 5 years at a rate of -4.6% per year.

Accelerating Growth: Unable to compare 1T3's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1T3 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: 1T3 has a negative Return on Equity (-138.24%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Syndax Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 1T3's short term assets ($74.9M) exceeds its short term liabilities ($18.3M)

Long Term Liabilities: 1T3's short term assets ($74.9M) exceeds its long term liabilities (14.0M)


Debt to Equity History and Analysis

Debt Level: 1T3 is debt free.

Reducing Debt: 1T3 currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: 1T3 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 1T3's debt is not covered by short term assets (assets are -3.3709443210868E+17x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1T3 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 1T3 has sufficient cash runway for 1.164257 years if free cash flow continues to reduce at historical rates of -21% each year.


Next Steps

Dividend

What is Syndax Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 1T3's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 1T3's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1T3's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1T3's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1T3's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Syndax Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

4.4yrs

Average management tenure


CEO

Briggs Morrison (59yo)

4.4yrs

Tenure

US$2,080,513

Compensation

Dr. Briggs W. Morrison, M.D. serves as the Executive Partner MPM Capital. He joined MPM in 2015. He served as the Chairman of Scientific Advisory Board at ABIONYX Pharma SA (formerly, Cerenis Therapeutics  ...


CEO Compensation Analysis

Compensation vs Market: Briggs's total compensation ($USD2.08M) is above average for companies of similar size in the German market ($USD513.69K).

Compensation vs Earnings: Briggs's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

4.4yrs

Average Tenure

60.5yo

Average Age

Experienced Management: 1T3's management team is considered experienced (4.4 years average tenure).


Board Age and Tenure

3.3yrs

Average Tenure

57.5yo

Average Age

Experienced Board: 1T3's board of directors are considered experienced (3.3 years average tenure).


Insider Trading

Insider Buying: 1T3 insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$53,95911 Oct 19
Briggs Morrison
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares11,000
Max PriceUS$4.91
BuyUS$135,54213 May 19
Briggs Morrison
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares20,400
Max PriceUS$6.73
BuyUS$4,82625 Mar 19
Michael Meyers
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares1,112
Max PriceUS$4.35

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.7%.


Management Team

  • Rick Shea (67yo)

    CFO & Treasurer

    • Tenure: 2.8yrs
    • Compensation: US$13.00k
  • Ed Sausville

    • Tenure: 0yrs
  • Ronald Evans

    Co-Founder

    • Tenure: 3.3yrs
  • Michael Metzger (48yo)

    President

    • Tenure: 0.3yrs
    • Compensation: US$1.52m
  • Rich Heyman (62yo)

    Co-Founder

    • Tenure: 0yrs
  • Peter Ordentlich (50yo)

    Co-Founder & Chief Scientific Officer

    • Tenure: 14.1yrs
  • Michael Downes

    Co-Founder

    • Tenure: 0yrs
  • Briggs Morrison (59yo)

    CEO & Director

    • Tenure: 4.4yrs
    • Compensation: US$2.08m
  • Luke Albrecht

    General Counsel & Corporate Secretary

    • Tenure: 0yrs
  • Michael Meyers (68yo)

    Chief Medical Officer

    • Tenure: 4.3yrs
    • Compensation: US$1.05m

Board Members

  • Jay Lichter (57yo)

    Observer

    • Tenure: 0yrs
  • Keith Katkin (48yo)

    Independent Director

    • Tenure: 2.7yrs
    • Compensation: US$209.91k
  • Pierre Legault (58yo)

    Independent Director

    • Tenure: 2.8yrs
    • Compensation: US$223.16k
  • Dennis Podlesak (61yo)

    Chairman

    • Tenure: 10.9yrs
    • Compensation: US$245.16k
  • George Sledge (67yo)

    Member of Scientific Advisory Board

    • Tenure: 2.6yrs
    • Compensation: US$23.05k
  • Ronald Evans

    Co-Founder

    • Tenure: 3.3yrs
  • Michael Metzger (48yo)

    President

    • Tenure: 0.3yrs
    • Compensation: US$1.52m
  • Fabrice Egros (56yo)

    Independent Director

    • Tenure: 6.2yrs
    • Compensation: US$199.66k
  • Briggs Morrison (59yo)

    CEO & Director

    • Tenure: 4.4yrs
    • Compensation: US$2.08m
  • Julie Brahmer

    Member of Scientific Advisory Board

    • Tenure: 3.9yrs

Company Information

Syndax Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Syndax Pharmaceuticals, Inc.
  • Ticker: 1T3
  • Exchange: DB
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$191.340m
  • Listing Market Cap: US$173.507m
  • Shares outstanding: 27.14m
  • Website: https://www.syndax.com

Number of Employees


Location

  • Syndax Pharmaceuticals, Inc.
  • 35 Gatehouse Drive
  • Building D
  • Waltham
  • Massachusetts
  • 2451
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1T3DB (Deutsche Boerse AG)YesCommon StockDEEURMar 2016
SNDXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMar 2016

Biography

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company’s lead product candidates include entinostat, which is in Phase III cli ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/22 21:55
End of Day Share Price2019/11/22 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.